4.6 Article

miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer

期刊

INTERNATIONAL JOURNAL OF ONCOLOGY
卷 39, 期 1, 页码 13-21

出版社

SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2011.1012

关键词

microRNA; miR-218; array-comparative genomic hybridization; 4p15.31; bladder cancer

类别

资金

  1. Ministry of Education, Science, Sports and Culture [20390427, 20591861]
  2. Grants-in-Aid for Scientific Research [20390427, 23791764, 20591861] Funding Source: KAKEN

向作者/读者索取更多资源

Growing evidence suggests that microRNAs (miRNAs) are aberrantly expressed in many human cancers, and that they play significant roles in carcinogenesis and cancer progression. The identification of tumor suppressive miRNAs and their target genes could provide new insights into the mechanism of carcinogenesis. However, the genetic or epigenetic regulations of these miRNAs have not yet been fully elucidated in bladder cancer (BC). Chromosomal alterations of cancer cells give us important information for the identification of tumor suppressor genes. Our miRNA array-comparative genomic hybridization (CGH) analysis showed several miRNAs to be candidate tumor suppressors of BC. Our array-CGH analysis revealed that chromosome 4 was lost in all BC cell lines. We selected 19 miRNAs located on chromosome 4 and evaluated their expression levels in cancer cell lines as well as clinical samples. Gain-of-function analysis revealed that miR-218 inhibited BC cell proliferation, migration and invasion. Furthermore, flow cytometry analysis showed that it induced BC cell apoptosis. Genome-wide gene expression analysis showed that it targeted multiple oncogenes in BC. Our study is the first to demonstrate that miR-218 located on chrosomosme 4p15.31 is a tumor suppressive miRNA in BC. The identification of tumor suppressive miRNAs and their target genes on the basis of array-CGH analysis could provide new insights into the mechanisms of BC carcinogenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma

Kazuki Kuroshima, Hirofumi Yoshino, Shunsuke Okamura, Masafumi Tsuruda, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Shuichi Tatarano, Masayuki Nakagawa, Hideki Enokida

CANCER SCIENCE (2020)

Article Oncology

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation

Hirofumi Yoshino, Hideki Enokida, Yoichi Osako, Nijiro Nohata, Masaya Yonemori, Satoshi Sugita, Kazuki Kuroshima, Masafumi Tsuruda, Shuichi Tatarano, Masayuki Nakagawa

MOLECULAR ONCOLOGY (2020)

Article Multidisciplinary Sciences

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant

Masafumi Tsuruda, Hirofumi Yoshino, Shunsuke Okamura, Kazuki Kuroshima, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Shuichi Tatarano, Masayuki Nakagawa, Hideki Enokida

PLOS ONE (2020)

Article Immunology

Successful Kidney Transplantation Alone With Severe Left Ventricular Systolic Dysfunction of Ejection Fraction 14%: A Case Report

Yasutoshi Yamada, Hideki Enokida, Hiroki Harada, Saiki Saito, Taichi Miyauchi, Shuji Nagatomi, Masato Minami, Akihiko Mitsuke, Tomoaki Ishihara, Hiroaki Nishimura, Shuichi Tatarano, Norihiko Goto, Yuichi Akasaki, Masayuki Nakagawa

TRANSPLANTATION PROCEEDINGS (2020)

Article Multidisciplinary Sciences

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma

Hirofumi Yoshino, Yasutoshi Yamada, Hideki Enokida, Yoichi Osako, Masafumi Tsuruda, Kazuki Kuroshima, Takashi Sakaguchi, Satoshi Sugita, Shuichi Tatarano, Masayuki Nakagawa

PLOS ONE (2020)

Article Oncology

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer

Shunsuke Okamura, Hirofumi Yoshino, Kazuki Kuroshima, Masafumi Tsuruda, Yoichi Osako, Takashi Sakaguchi, Masaya Yonemori, Yasutoshi Yamada, Shuichi Tatarano, Masayuki Nakagawa, Hideki Enokida

Summary: The study established cisplatin-resistant BC cell lines and identified miR-486-5p as a tumor suppressor microRNA that targets EHHADH gene, affecting cancer cell proliferation, migration, invasion, and cisplatin sensitivity.

BMC CANCER (2021)

Article Oncology

Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort

Katsuhiro Ito, Takashi Kobayashi, Takahiro Kojima, Kensuke Hikami, Takeshi Yamada, Kosuke Ogawa, Kenji Nakamura, Naoto Sassa, Akira Yokomizo, Takashige Abe, Kazunari Tsuchihashi, Shuichi Tatarano, Junichi Inokuchi, Ryotaro Tomida, Maki Fujiwara, Atsushi Takahashi, Kazumasa Matsumoto, Kosuke Shimizu, Hiromasa Araki, Ryoma Kurahashi, Yu Osaki, Yu Tashiro, Masayuki Uegaki, Osamu Ogawa, Hiroshi Kitamura, Hiroyuki Nishiyama

Summary: The study found that despite comparable safety profiles, patients with PS >= 2 showed worse overall response rates and overall survival compared to those with PS <= 1. Among patients with impaired performance status, those with NLR <3.5 and no liver metastasis may benefit the most from pembrolizumab therapy.

CANCER MEDICINE (2021)

Article Urology & Nephrology

Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab

Minoru Kato, Takashi Kobayashi, Yoshiyuki Matsui, Katsuhiro Ito, Kensuke Hikami, Takeshi Yamada, Kosuke Ogawa, Kenji Nakamura, Naoto Sassa, Akira Yokomizo, Takashige Abe, Kazunari Tsuchihashi, Shuichi Tatarano, Junichi Inokuchi, Ryotaro Tomida, Maki Fujiwara, Atsushi Takahashi, Kazumasa Matsumoto, Kosuke Shimizu, Hiromasa Araki, Ryoma Kurahashi, Yu Ozaki, Yu Tashiro, Masayuki Uegaki, Takahiro Kojima, Junji Uchida, Osamu Ogawa, Hiroyuki Nishiyama, Hiroshi Kitamura

Summary: This study investigated the impact of chemotherapy cycles and response on overall survival in metastatic urothelial carcinoma patients treated with pembrolizumab. The results showed that the therapeutic benefit of pembrolizumab can be expected regardless of the response to or number of cycles of platinum-based first-line chemotherapy.

INTERNATIONAL JOURNAL OF UROLOGY (2021)

Meeting Abstract Oncology

Randomized controlled trial of GnRH antagonist monotherapy versus GnRH agonist plus bicalutamide (CAB) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) (KYUCOG-1401).

Akira Yokomizo, Futoshi Morokuma, Masatoshi Eto, Masaki Shiota, Hideyasu Matsuyama, Hiroaki Matsumoto, Toshiyuki Kamoto, Naoki Terada, Kazuya Kawahara, Hideki Enokida, Shuichi Tatarano, Naohiro Fujimoto, Katsuyoshi Higasijima, Hideki Sakai, Tomoaki Hakariya, Tsukasa Igawa, Shigetaka Suekane, Tomomi Kamba, Yutaka Sugiyama, Seiji Naito

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1

Motoki Tamai, Shuichi Tatarano, Shunsuke Okamura, Wataru Fukumoto, Issei Kawakami, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Masaya Yonemori, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, Hirofumi Yoshino

Summary: MiR-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer cells by targeting SMARCD1, thereby inhibiting cell growth and restoring sensitivity to gemcitabine.

MOLECULAR ONCOLOGY (2022)

Article Urology & Nephrology

Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients

Shuichi Tatarano, Akihiko Mitsuke, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Hirofumi Yoshino, Hiroaki Nishimura, Yasutoshi Yamada, Hideki Enokida

Summary: This study analyzed the clinical outcomes of laparoscopic adrenalectomy for pheochromocytomas in hemodialysis compared with nonhemodialysis patients. The results showed that increasing intravascular volume before surgery in hemodialysis patients made perioperative hemodynamic management safer. The study also found that an increase in systolic blood pressure at CO2 insufflation was an independent predictor of a hypertensive spike during the surgery.

INTERNATIONAL JOURNAL OF NEPHROLOGY (2022)

Article Biochemistry & Molecular Biology

Exosomal microRNA-1 and MYO15A as a target for therapy and diagnosis in renal cell carcinoma

Hirofumi Yoshino, Shuichi Tatarano, Motoki Tamai, Masafumi Tsuruda, Sayaka Iizasa, Junya Arima, Issei Kawakami, Wataru Fukumoto, Ichiro Kawahara, Gang Li, Takashi Sakaguchi, Satoru Inoguchi, Yasutoshi Yamada, Hideki Enokida

Summary: Exosomes containing miR-1 were found to inhibit tumor growth in renal cell carcinoma (RCC), and the study explored the functional role of exosomal miR-1 and its potential as a tumor marker in RCC.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)

Article Oncology

Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study

Masaki Shiota, Shuichi Tatarano, Toshiyuki Kamoto, Hideyasu Matsuyama, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Naohiro Fujimoto, Yuya Sekine, Hiroko Kimura, Shintaro Narita, Naoki Terada, Yukihide Momozawa, Shusuke Akamatsu, Tomonori Habuchi, Akira Yokomizo, Seiji Naito, Masatoshi Eto

Summary: This study aimed to identify genetic markers that could predict the outcome of androgen-deprivation therapy (ADT) for advanced prostate cancer. Through a genome-wide association study (GWAS), single-nucleotide polymorphisms (SNPs) associated with radiographic progression-free survival (rPFS) and adverse events (AEs) were identified. Validation studies confirmed the association of these SNPs with ADT outcomes, and a genetic prognostic model using these SNPs showed excellent predictive efficacy for progression-free survival and overall survival. The study also revealed SNPs associated with AEs in ADT, such as de novo diabetes mellitus, arthralgia, and de novo dyslipidemia.

ENDOCRINE-RELATED CANCER (2023)

Article Urology & Nephrology

Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery

Shuichi Tatarano, Hideki Enokida, Masaya Yonemori, Rumiko Eura, Hirofumi Yoshino, Hiroaki Nishimura, Yasutoshi Yamada, Masayuki Nakagawa

Summary: The study found that the incidence of pre-DVT was 6.3% in patients undergoing urological surgery. Elderly patients and/or a cutoff D-dimer level of 1.8 μg/mL might be good indicators for pre-DVT screening by CUS. No patient developed symptomatic VTE during the 90-day postoperative follow-up period.

INVESTIGATIVE AND CLINICAL UROLOGY (2021)

Correction Oncology

Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study (vol 50, pg 66, 2020)

Hideki Enokida, Yasutoshi Yamada, Shuichi Tatarano, Hirofumi Yoshino, Masaya Yonemori, Takashi Sakaguchi, Hiroaki Nishimura, Rumiko Eura, Masayuki Nakagawa

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)

暂无数据